| Efficacy and safety of vismodegib in advanced basal-cell carcinoma A Sekulic, MR Migden, AE Oro, L Dirix, KD Lewis, JD Hainsworth, ... New England Journal of Medicine 366 (23), 2171-2179, 2012 | 1466 | 2012 |
| Inhibition of the hedgehog pathway in advanced basal-cell carcinoma DD Von Hoff, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, ... New England Journal of Medicine 361 (12), 1164-1172, 2009 | 1291 | 2009 |
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 CM Rudin, CL Hann, J Laterra, RL Yauch, CA Callahan, L Fu, T Holcomb, ... New England Journal of Medicine 361 (12), 1173-1178, 2009 | 1162 | 2009 |
| A paracrine requirement for hedgehog signalling in cancer RL Yauch, SE Gould, SJ Scales, T Tang, H Tian, CP Ahn, D Marshall, ... Nature 455 (7211), 406-410, 2008 | 1140 | 2008 |
| Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer CM Rudin, S Durinck, EW Stawiski, JT Poirier, Z Modrusan, DS Shames, ... Nature genetics 44 (10), 1111-1116, 2012 | 991 | 2012 |
| Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma RL Yauch, GJP Dijkgraaf, B Alicke, T Januario, CP Ahn, T Holcomb, ... Science 326 (5952), 572-574, 2009 | 957 | 2009 |
| Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading SD Miller, CL Vanderlugt, WS Begolka, W Pao, RL Yauch, KL Neville, ... Nature medicine 3 (10), 1133-1136, 1997 | 688 | 1997 |
| Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients RL Yauch, T Januario, DA Eberhard, G Cavet, W Zhu, L Fu, TQ Pham, ... Clinical Cancer Research 11 (24), 8686-8698, 2005 | 631 | 2005 |
| Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome JY Tang, JM Mackay-Wiggan, M Aszterbaum, RL Yauch, J Lindgren, ... New England Journal of Medicine 366 (23), 2180-2188, 2012 | 604 | 2012 |
| A comprehensive transcriptional portrait of human cancer cell lines C Klijn, S Durinck, EW Stawiski, PM Haverty, Z Jiang, H Liu, J Degenhardt, ... Nature biotechnology 33 (3), 306-312, 2015 | 588 | 2015 |
| The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix M Ohh, RL Yauch, KM Lonergan, JM Whaley, AO Stemmer-Rachamimov, ... Molecular cell 1 (7), 959-968, 1998 | 583 | 1998 |
| Somatic mutations lead to an oncogenic deletion of met in lung cancer M Kong-Beltran, S Seshagiri, J Zha, W Zhu, K Bhawe, N Mendoza, ... Cancer research 66 (1), 283-289, 2006 | 511 | 2006 |
| Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer DR Spigel, TJ Ervin, RA Ramlau, DB Daniel, JH Goldschmidt Jr, ... Journal of clinical oncology 31 (32), 4105, 2013 | 486 | 2013 |
| Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug ResistanceMechanisms of Resistance to a Hedgehog Pathway Inhibitor GJP Dijkgraaf, B Alicke, L Weinmann, T Januario, K West, Z Modrusan, ... Cancer research 71 (2), 435-444, 2011 | 395 | 2011 |
| Highly stoichiometric, stable, and specific association of integrin α3β1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration RL Yauch, F Berditchevski, MB Harler, J Reichner, ME Hemler Molecular biology of the cell 9 (10), 2751-2765, 1998 | 391 | 1998 |
| Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma HJ Sharpe, G Pau, GJ Dijkgraaf, N Basset-Seguin, Z Modrusan, ... Cancer cell 27 (3), 327-341, 2015 | 372 | 2015 |
| Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice J Lau, J Cheung, A Navarro, S Lianoglou, B Haley, K Totpal, L Sanders, ... Nature communications 8 (1), 14572, 2017 | 298 | 2017 |
| Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors A Daemen, D Peterson, N Sahu, R McCord, X Du, B Liu, K Kowanetz, ... Proceedings of the National Academy of Sciences 112 (32), E4410-E4417, 2015 | 284 | 2015 |
| Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. DR Spigel, TJ Ervin, R Ramlau, DB Daniel, JH Goldschmidt, ... Journal of Clinical Oncology 29 (15_suppl), 7505-7505, 2011 | 273 | 2011 |
| Reproducible pharmacogenomic profiling of cancer cell line panels PM Haverty, E Lin, J Tan, Y Yu, B Lam, S Lianoglou, RM Neve, S Martin, ... Nature 533 (7603), 333-337, 2016 | 262 | 2016 |
